Location & Type arrow_drop_up Concepts arrow_drop_down Orgs arrow_drop_down
#1
Jonathan Friedberg
Jonathan Friedberg
The coonsoldated Department of Psychatry, the Neuroscience Program, Harvard Medical School, Boston, Mass, Consolidated Department of Psychiatry, the Neuro‐science ...
Known for star star star star star
Indolent Lymphoma | Phase Iii | Free Survival | Evaluate Vitamin
#2
Julie Marie Vose
Julie Marie Vose
From the Section of Oncology-Hematology, Department of Internal Medicine, University of Nebraska Medical Center the Department of Internal Medicine, Omaha Veterans Affairs ...
Known for star star star star star_border
Advisory Committees | Entitys Board | Follicular Lymphoma | Speakers Bureau

#3
Jason Robert Westin
Jason Robert Westin
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Unit 429, 1515 Holcombe Blvd, 77030, Houston, TX, USA
Known for star star star star star_border
Advisory Committees | Entitys Board | B-Cell Lymphoma | Speakers Bureau
#4
Eva K. Kimby
Eva K. Kimby
Department of Medicine, Section of Hematology, Danderyd Hospital, Danderyd, and the Department of Clinical Immunology, Huddinge Hospital, Huddinge, Sweden
Known for star star star star star_border
Follicular Lymphoma | Chronic Lymphocytic Leukemia | Advisory Committees | Rituximab Maintenance
#5
Krimo Bouabdallah
Krimo Bouabdallah
CHU Bordeaux, Service d’Hématologie et Thérapie Cellulaire, Bordeaux, France
Known for star star star star star_border
Advisory Committees | Entitys Board | Speakers Bureau | Intensive Chemotherapy
#6
Harald JR. Holte
Harald JR. Holte
From the Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia (S.J.S.); the Hematopoietic Cellular Therapy Program, University of Chicago ...
Known for star star star star star_border
Advisory Committees | Entitys Board | Follicular Lymphoma | High-Dose Therapy
#7
Anca A. Prica
Anca A. Prica
From the Joint Department of Medical Imaging, University Health Network, Mount Sinai Hospital & Women's College Hospital, University of Toronto, 610 University Ave, Suite ...
Known for star star star star star_border
Hematologic Malignancies | Advisory Committees | Drug Wastage | Entitys Board
#8
David C. Hodgson
David C. Hodgson
Division of Radiation Oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada, ; Department of Radiation Oncology, University of Toronto, Toronto, ON, Canada, ;
Known for star star star star star_border
Hodgkin Lymphoma | Radiation Therapy | Breast Cancer | Late Effects
#9
Eleanor Neal
Eleanor Neal
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
Known for star star star star star_border
Baseline Pet | Rituximab Maintenance | Immunologic Doublet | Indolent Lymphoma
#10
Stacey Kalambakas
Stacey Kalambakas
Clinical Research Science, Celgene Corporation, Summit, United States
Known for star star star star star_border
Advisory Committees | Entitys Board | ≥ 70 | Phase Iii
#11
Ana Kostic
Ana Kostic
Juno Therapeutics, Inc., a Celgene Company, Seattle, WA
Known for star star star star star_border
Equity Ownership | Speakers Bureau | Lisocabtagene Maraleucel | Transcend Nhl
#12
Roswitha Forstpointner
Roswitha Forstpointner
Department of Internal Medicine III, Ludwig-Maximilians-University Hospital Munich, Munich, Germany
Known for star star star star star_border
Follicular Lymphoma | Rituximab Maintenance | Response Duration | Stem Cells
#13
Chengqing Wu
Chengqing Wu
Statistics, Celgene International, Boudry, Switzerland
Known for star star star star star_border
Advisory Committees | Entitys Board | ≥ 70 | Phase Iii
#14
Steven W. Papish
Steven W. Papish
Hematology-Oncology Associates of Northern New Jersey, Morristown, NJ, USA,
Known for star star star star star_border
Speakers Bureau | Small Lymphocytic Lymphoma | Untreated Chronic Lymphocytic Leukemia | Sarah Cannon
#15
Roy Louis Maute
Roy Louis Maute
Institute of Cancer Genetics and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA
Known for star star star star star_border
Anti-Cd47 Antibody | Orofacial Clefting | Mhc Class | Pd-1 Expression
#16
Elisa Santambrogio
Elisa Santambrogio
Unit of Hematology, Città della Salute e della Scienza, Turin, Italy - esantambrogio@cittadellasalute.to.it.
Known for star star star star star_border
Advisory Committees | Entitys Board | Speakers Bureau | Hematological Disorders
#17
Peter D. Brown
Peter D. Brown
Cephalon, Inc., Frazer, PA, USA,
Known for star star star star star_border
Omacetaxine Mepesuccinate | Advisory Committees | Tyrosine-Kinase Inhibitors | Chronic Phase

 

Recently Asked Questions

View all FAQs

Cryptococcal Meningitis Cryptococcal meningitis is a serious brain infection caused by the Cryptococcus neoformans fungus. The fungus is found in soil and bird droppings, and can...

 

Childhood schizophrenia is a rare but serious mental disorder that affects children. Early onset schizophrenia typically appears in children between the...

 

Alcoholic Ketoacidosis Alcoholic ketoacidosis (AKA) is a medical emergency that can occur in people with alcoholism. It is caused by a build-up of ketones in the body, which can...

 

Serous Carcinoma Serous Carcinoma is a cancer which forms in the serous membrane. The serous membrane is a thin layer of tissue which covers and protects the organs in the...

 

Dislocated Knee A dislocated knee is a serious injury that can occur when the bones of the lower leg are forced out of alignment. The knee is a complex joint that is made...

 

Whole Exome And Transcriptome Sequencing In 1042 Cases Reveals Distinct...

[ PUBLICATION ] Follicular Lymphoma (FL) is the most common indolent lymphoma derived from light zone germinal center B cells and characterized by a t(14;18) translocation resulting in upregulation of BCL2 in ...
Known for star star star star star
Follicular Lymphoma | Advisory Committees | Entitys Board | Transcriptome Sequencing

A Phase I/ii Study Of Lenalidomide Plus Obinutuzumab In Relapsed Indolent Lymphoma

[ PUBLICATION ] Background: Patients with advanced indolent non-Hodgkin lymphoma (iNHL) can develop chemoresistance and most relapse following standard therapy. Although multiple treatment options exist, most ...
Known for star star star star star
Advisory Board | Relapsed Indolent Lymphoma | Consultancy Funding | Phase Portion

Two-Year Follow-Up Of Transcend Nhl 001, A Multicenter Phase 1 Study Of...

[ PUBLICATION ] Abstract Background : LBCLs are prevalent and aggressive subtypes of NHL, with limited treatment options and historically poor outcomes in the third- or later-line setting. Liso-cel is an ...
Known for star star star star star_half
Consultancy Honoraria | Speakers Bureau | Transcend Nhl | Advisory Committees

Cd5-Positive Marginal Zone Lymphoma: Clinical Characteristics Of The Mskcc...

[ PUBLICATION ] ... Zone Lymphoma (MZL) includes three subtypes of indolent lymphoma: splenic MZL, extranodal MZL of mucosa-associated lymphoid tissue (MALT) and nodal MZL. The diagnosis of MZL is often made ...
Known for star star star star star_half
Consultancy Funding | Marginal Zone | Cd5- Mzl | Seattle Genetics

Phase Ii Trial Of Response Adapted Ultra Low Dose (Uld) Orbital Radiation Therapy...

[ PUBLICATION ] Abstract Introduction: The standard of care for patients with stage IE indolent B-cell lymphoma (BCL) of the ocular adnexa is external beam radiotherapy (RT) to 24-30 Gy. Even with these ...
Known for star star star star star_half
Consultancy Funding | Response Adapted | Gilead Company | Bristol Myers Squibb

Long-Term Efficacy And Safety From The Copanlisib Chronos-1 Study In Patients...

[ PUBLICATION ] Abstract Introduction: We have previously reported that treatment of patients with relapsed or refractory indolent B-cell lymphoma with the pan-class I phosphatidylinositol 3-kinase ...
Known for star star star star star_half
Advisory Committees | Entitys Board | Speakers Bureau | Consultancy Honoraria

An Open-Label, Randomized Study Of Bendamustine And Rituximab (Br) Compared With...

[ PUBLICATION ] Abstract Abstract 902 Background Bendamustine (B) is an active agent for relapsed and refractory indolent NHL, both as monotherapy and combined with ...
Known for star star star star star_half
Cvp Chop | Advisory Committees | Entitys Board | Indolent Nhl

Outcomes For Patients With Pre-Existing Diabetes Or Hypertension Treated With...

[ PUBLICATION ] Abstract Introduction: We previously reported that treatment of patients with relapsed or refractory indolent B-cell lymphoma with the pan-class I phosphatidylinositol 3-kinase (PI3K) ...
Known for star star star star star_half
Advisory Committees | Entitys Board | Speakers Bureau | Membership Entity

Results Of A Phase I Trial Of Lenalidomide, Rituximab (R2) And Ixazomib For...

[ PUBLICATION ] ... with indolent B-cell lymphoma including follicular lymphoma (FL). Recent phase III data from the RELEVANCE trial comparing R2 to traditional chemoimmunotherapy showed that this regimen is ...
Known for star star star star star_half
Non-Hodgkin Lymphoma | Consultancy Honoraria | Advisory Committees | Relevance Trial

A Phase I Study Of Lenalidomide Plus A Next Generation Anti-Cd20 Antibody,...

[ PUBLICATION ] Abstract Background: Patients with advanced indolent non-Hodgkin lymphoma (iNHL) can develop chemoresistance and most relapse following standard therapy. Lenalidomide activates NK cells ...
Known for star star star star star_half
Advisory Committees | Entitys Board | Generation Anti-Cd20 Antibody | Relapsed Indolent Lymphoma